Journal of integrative medicine · 2026
Yinchenhao Decoction, a compound Chinese herbal medicine, for patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Fei-Peng, Yang Chen, Yu Shang-Hai, Cai Hong, Hui Meng-Yu, Fang Ling-Ling, Chen Gao-Feng, Jiang Shi-Li, Qi Shen-Lan, Wu Si-Jia, Liu Si-Jie, Yuan Jie, Xu Gang, Liu Wei, Liu Ping, Zhang Hua
Аннотация
BACKGROUND: The incidence of nonalcoholic fatty liver disease (NAFLD) is increasing. Yinchenhao Decoction (YCHD) has been well studied for its uses in treating NAFLD. Moreover, the metabolism of bile acids (BAs) and eicosanoids have influence on NAFLD. YCHD is a classic prescription for damp-heat syndrome, and can regulate BA metabolism and alleviate inflammation in NAFLD.
OBJECTIVE: This study evaluated the effects of YCHD on NAFLD and explored the effect of YCHD on eicosanoids and BAs.
DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: This randomized, double-blind, placebo-controlled trial enrolled 130 NAFLD participants. The participants were randomly assigned to YCHD group or placebo group in a 1:1 ratio, receiving YCHD granules or the placebo for 24 weeks.
OUTCOME MEASURES: Primary outcome was absolute change in liver magnetic resonance imaging proton density fat fraction (MRI-PDFF) from the baseline to week 24. Secondary outcomes included absolute changes in controlled attenuation parameter (CAP), metabolic parameters, and liver injury and function parameters.
RESULTS: After 24 weeks of treatment, MRI-PDFF (average), CAP, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and body mass index (BMI) decreased significantly in the YCHD group compared to placebo group (all P < 0.05). Moreover, no serious adverse events were observed. Further, YCHD did not significantly regulate eicosanoids (all P > 0.05); however it did regulate taurodeoxycholic acid (TDCA), glycodeoxycholic acid (GDCA), deoxycholic acid (DCA), glycolithocholic acid (GLCA), and the ratio of GDCA to total BAs, compared to the placebo at week 24 (P < 0.05).
CONCLUSION: YCHD can reduce the MRI-PDFF, CAP, ALT, AST, ALP and BMI without significant adverse events. YCHD can also regulate the metabolism of TDCA, GDCA and DCA, and the ratio of GDCA to total BAs.
TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2000034868. Please cite this article as: Xu FP, Yang C, Yu SH, Cai H, Hui MY, Fang LL, Chen GF, Jiang SL, Qi SL, Wu SJ, Liu SJ, Yuan J, Xu G, Liu W, Liu P, Zhang H. Yinchenhao Decoction, a compound Chinese herbal medicine, for patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. J Integr Med. 2026; 24(3):365-375.
OBJECTIVE: This study evaluated the effects of YCHD on NAFLD and explored the effect of YCHD on eicosanoids and BAs.
DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: This randomized, double-blind, placebo-controlled trial enrolled 130 NAFLD participants. The participants were randomly assigned to YCHD group or placebo group in a 1:1 ratio, receiving YCHD granules or the placebo for 24 weeks.
OUTCOME MEASURES: Primary outcome was absolute change in liver magnetic resonance imaging proton density fat fraction (MRI-PDFF) from the baseline to week 24. Secondary outcomes included absolute changes in controlled attenuation parameter (CAP), metabolic parameters, and liver injury and function parameters.
RESULTS: After 24 weeks of treatment, MRI-PDFF (average), CAP, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and body mass index (BMI) decreased significantly in the YCHD group compared to placebo group (all P < 0.05). Moreover, no serious adverse events were observed. Further, YCHD did not significantly regulate eicosanoids (all P > 0.05); however it did regulate taurodeoxycholic acid (TDCA), glycodeoxycholic acid (GDCA), deoxycholic acid (DCA), glycolithocholic acid (GLCA), and the ratio of GDCA to total BAs, compared to the placebo at week 24 (P < 0.05).
CONCLUSION: YCHD can reduce the MRI-PDFF, CAP, ALT, AST, ALP and BMI without significant adverse events. YCHD can also regulate the metabolism of TDCA, GDCA and DCA, and the ratio of GDCA to total BAs.
TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2000034868. Please cite this article as: Xu FP, Yang C, Yu SH, Cai H, Hui MY, Fang LL, Chen GF, Jiang SL, Qi SL, Wu SJ, Liu SJ, Yuan J, Xu G, Liu W, Liu P, Zhang H. Yinchenhao Decoction, a compound Chinese herbal medicine, for patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. J Integr Med. 2026; 24(3):365-375.